GB2550363A - Compound - Google Patents

Abstract

Compound according to formula (I) or a salt, ester, solvate, N-oxide, or prodrug thereof, where the substituents are as defined in the claims. Preferably R6 is H, R10 is H, and R2 is a methoxyethoxy substituent. Preferable compounds are 2-(2-methoxyethoxy)-1-(thiazol-2-yl)ethan-1-one and 13-(thiazol-2-yl)-2,5,8,11-tetraoxatridecan-13-one. Compounds according to formula I may be used in therapy, especially in the treatment or prevention of a chronic inflammatory condition or hyperproliferative disorder. Also claimed are compounds according to formula II or a salt, ester, solvate, N-oxide, or prodrug thereof for use in the treatment or prevention of a chronic inflammatory condition or hyperproliferative disorder.

Description

Compound

The invention relates to certain new 2-oxothiazole compounds and to pharmaceutical compositions comprising said compounds. This invention also relates to the use of the compounds of the invention and reduced equivalents thereof, i.e. 2-hydroxylthiazole compounds for use in the prevention, treatment or alleviation of symptoms of chronic inflammatory disorders such as glomerulonephritis, rheumatoid arthritis and psoriasis as well as chronic inflammatory disorders associated with a diabetic condition in a patient, particularly diabetes mellitus, such as diabetic nephropathy and diabetic retinopathy. In another embodiment, this invention relates to the use of the compounds of the invention or reduced equivalents thereof, i.e. 2-hydroxylthiazole compounds for use in the prevention or treatment of hyperproliferative disorders such as cancer. Alternatively, compounds of formula (I) can be used as intermediates in the synthesis of other interesting 2-oxothiazole compounds.

Background

Mammalian cells contain a large number of phospholipases that hydrolyse phospholipids in a structurally specific manner for production of a myriad of products, many of which have potent biological activity. There has been considerable interest in characterising these enzymes because of their role in production of lipid mediators of inflammation. Since the first studies 20 years ago showing that mammalian cells contain a cystolic calcium dependent phospholipase A2 (cPLA2) specific for arachidonic acid, an extensive amount of evidence has substantiated a primary role for CPLA2 as the key enzyme that mediates the release of arachidonic acid for the production of eicosanoids.

The enzyme CPLA2 contributes to the pathogenesis of a variety of diseases particularly those in which inflammation plays a primary role implicating a role for inflammatory lipid mediators in disease pathogenesis. The inhibition therefore of such lipase enzymes offers a potential therapy for inflammatory conditions in particular chronic inflammatory conditions such as those above, psoriasis and glomerulonephritis.

The phospholipase A2s are a group of enzymes that release unsaturated fatty acids from the sn2 position of membrane phospholipids. Once released, the fatty acids are converted by various enzymes into biologically very important signalling molecules. Release of arachidonate initiates the arachidonate cascade leading to the synthesis of eicosanoids such as prostaglandins.

Eicosanoids are important in a variety of physiological processes and play a central role in inflammation. In Inflammation, Vol. 18, No. 1 1994, Andersen et al identify the presence of certain phospholipase A2s in psoriatic human skin.

It is therefore believed that inhibition of phospholipase A2 enzymes should have potential in preventing, treating, reducing the severity of, or curing some of the inflammatory symptoms, including but not limited to epidermal hyperproliferation due to increased leukotriene production, related to eicosanoid production and cell activation in both epidermis and dermis in psoriasis. Of particular interest are inhibitors of the CPLA2 enzyme.

The present inventors seek new phospholipase A2 inhibitors and particularly use of such inhibitors for the treatment or prevention of, inter alia, chronic inflammatory conditions such as glomerulonephritis and associated conditions like diabetic nephropathy and retinopathy, psoriasis, dermatitis, rheumatoid arthritis and hyperproliferative disorders such as cancer.

SUMMARY OF THE INVENTION

The present inventors have surprisingly found that certain 2-oxothiazoles or reduced equivalents, 2-hydroxylthiazole compounds are ideal CPLA2 inhibitors and offer new therapeutic routes to the prevention, treatment, reduction or alleviation of symptoms or curing of chronic inflammatory disorders such as glomerulonephritis and associated conditions like diabetic nephropathy and retinopathy, psoriasis, dermatitis, rheumatoid arthritis and hyperproliferative disorders such as cancer.

In a further aspect, the present inventors have also found that the compounds of the present invention offer value in the prevention or treatment of hyperproliferative disorders (defined below) such as cancer.

Thus, viewed from one aspect the invention provides a compound of formula (I)

wherein Re is H, Ci-ealkyl, -(CH2)pCOOH, -(CH2)pCOOCi.ealkyl, -(CH2)pCONH2, -(CH2)pCONHCi.ealkyl, or -(CH2)pCON(Ci.ealkyl)2,

Rio is H or Ci-e alkyl; R2 is 0-(CH2)a-[0-(CH2)b]e-[0-(CH2)c]e-0-(CH2)ciCH3; p is 0 to 3; a is 1 to 3, such as 2; b is 1 to 3, such as 2; c is 1 to 3, such as 2; d is 0 to 2, such as 0; each e is 0 or 1; or a salt, ester, solvate, N-oxide, or prodrug thereof Viewed from another aspect the invention provides a compound of formula (Π)

wherein R? isH, Ci-ealkyl, -(CH2)pCOOH, -(CH2)pCOOCi-6alkyl, -(CH2)pCONH2, -(CH2)pCONHCi.6alkyl, or -(CH2)pCON(Ci.6alkyl)2,

Rs is H or Ci-e alkyl·

Rg is H, a Ci-ioalkyl group, -SCi-ioalkyl group or -OCi-ioalkyl group; and p is 0 to 3; or a salt, ester, solvate, N-oxide, or prodrug thereof for use in therapy, such as for use in the treatment or prevention of a chronic inflammatory condition or a hyperproliferative disorder.

Viewed from another aspect the invention provides a compound of formula (I) as hereinbefore defined for use in therapy.

Viewed from another aspect the invention provides a compound of formula (I) as herein defined for use in the treatment or prevention of a chronic inflammatory condition.

Viewed from another aspect the invention provides a compound of formula (I) as herein defined for use in the treatment or prevention of a hyperproliferative disorder.

Viewed from another aspect the invention provides a pharmaceutical composition comprising a compound of formula (I) or (II) as hereinbefore defined.

Viewed from another aspect the invention provides a method of treating or preventing a chronic inflammatory disorder comprising administering to a patient in need thereof an effective amount of a compound a compound of formula (I) or (II) as hereinbefore defined.

Viewed from another aspect the invention provides a method of treating or preventing a hyperproliferative disorder comprising administering to a patient in need thereof an effective amount of a compound of formula (I) or (II) as hereinbefore defined.

Definitions

In this specification, unless stated otherwise, the term "alkyl" includes both straight and branched chain alkyl radicals and may be methyl, ethyl, n-propyl, i-propyl, n-butyl, i- butyl, s-butyl, t-butyl, n-pentyl, i-pentyl, t-pentyl, neo-pentyl, n-hexyl, i-hexyl, or t- hexyl. Any alkyl group is preferably linear.

Detailed Description of Invention

This invention relates to a series of related compounds which have utility in the treatment or prevention of chronic inflammatory disorders and hyperproliferative disorders. The compounds may also act as intermediate species in the formation of other 2-oxothiazole compounds.

Compounds of Formula (II

In a first embodiment, the invention provides 2-oxothiazole compounds of formula (I)

wherein is H, Ci-ealkyl, -(CH2)pCOOH, -(CH2)pCOOCi.6alkyl, -(CH2)pCONH2, -(CH2)pCONHCi.6alkyl, or -(CH2)pCON(Ci.6alkyl)2,

Rio is H or Ci-6 alkyl· R2 is 0-(CH2)a-[0-(CH2)b]e-[0-(CH2)c]e-0-(CH2)dCH3; p is 0 to 3; a is 1 to 3, such as 2; b is 1 to 3, such as 2; c is 1 to 3, such as 2; d is 0 to 2, such as 0; each e is 0 or 1; or a salt, ester, solvate, N-oxide, or prodrug thereof.

In compounds of formula (I) it is preferred if Re is H, -(CH2)pCOOH, -(CH2)pCONH2 or -(CH2)pCOOCi.ealkyl.

The subscript p is preferably 0 or 1. A further preferred option is - COOCi. ealkyl or H. Most especially Re is H in compounds of formula (I).

Rio is preferably H.

The R2 group as a whole preferably forms a polyether chain comprising two, three, or four oxygen atoms. Ideally those atoms are linked via an ethylene linker. Thus the linker is easily synthesised from ethylene glycol. It is thus preferred if a is 2. It is preferred if b is 2. It is preferred if c is 2. It is preferred if d is 0. It is preferred if all of a-c are 2. It is preferred if all of a-c are 2 and d is 0.

It is preferred if all subscript e’s are 1 or all subscript e’s are 0.

It is preferred if R2 is 0-(CH2)a-0-(CH2)b-0-(CH2)c-0-Me or -0(CH2)a-0-Me.

Thus a preferred R2 group is O-CH2CH2OCH3 or OCH2CH2-OCH2CH2-OCH2CH2-OCH3. A further preferred embodiment is therefore a compound of formula (III)

wherein Re is Η, -(CH2)pC00H, -(CH2)pCONH2 or -(CH2)pCOOCi.6alkyl; p is 0 or 1, especially 0; R2 is 0-(CH2)a-0-(CH2)b-0-(CH2)c-0-(CH2)dMe or -(CH2)a-0-(CH2)dMe; a is 1 to 3, such as 2; b is 1 to 3, such as 2; c is 1 to 3, such as 2; and d is 0 to 2, such as 0; or a salt, ester, solvate, N-oxide, or prodrug thereof.

Most preferred compounds of formula (I) are:

or a salt, ester, solvate, N-oxide, or prodrug thereof Compounds of Formula (ΊΠ

In a second embodiment, the invention provides 2-hydroxylthiazole compounds of formula (II) for use in therapy:

wherein R7 is H, Ci-ealkyl, -(CH2)pC00H, -(CH2)pCOOCi.6alkyl, -(CH2)pCONH2, -(CH2)pCONHCi-6alkyl, or-(CH2)pCON(Ci.6alkyl)2,

Rs is H or C1.6 alkyl· R9 is H, a Ci-ioalkyl group, -SCi.ioalkyl group or -OCi.ioalkyl group; and p is 0 to 3; or a salt, ester, solvate, N-oxide, or prodrug thereof.

In compounds of formula (II) it is preferred if R? is preferably H, -(CH2)pCOOH, -(CH2)pCONH2 or -(CH2)pCOOCi.6alkyl.

The subscript p is preferably 0 or 1. A more preferred option is - COOCi. ealkyl.

Rs is preferably H.

It is preferred if the substituent R9 is in the meta or para position on the ring, especially para. R9 is preferably a Ci.ioalkyl group, -SCi.ioalkyl group or -OCi. loalkyl group, especially a C4-10 alkyl group such as a Co-io alkyl group. Preferred options for R9 are a C4-ioalkyl group, especially a Co-s alkyl group such as a Cs alkyl group. R9 alkyl groups are preferably linear. A preferred compound therefore is of formula (IV):

RvisH, -(CH2)pCOOH, -(CH2)pCONH2 or -(CH2)pCOOCi-6alkyl; p is 0 or 1; R9 is Ci-ioalkyl group, -SCi.ioalkyl group or -OCi.ioalkyl group, especially a C4.10 alkyl group such as a Ce-io alkyl group.

Most preferred compounds of formual (II) are:

or a salt, ester, solvate, N-oxide, or prodrug thereof.

The invention also provides a pharmaceutical composition comprising the compounds of formula (II) described above.

Synthesis

The manufacture of the compounds of the invention typically involves known literature reactions. For example, the formation of a 2-oxothiazole, the precursor to many of the claimed compounds, can be achieved by reaction of an aldehyde XCOH with thiazole in the presence of a base and subsequent oxidation of the hydroxyl to a ketone. The X group is obviously selected to form the desired side chain group or a precursor thereof

These reactions are summarised in Scheme 1 below.

Scheme 1. (a) thiazole, base, (b) oxidation, e.g. Dess-Martin periodinane.

It will be appreciated that in the scheme above and many of those below, specific reagents and solvents may mentioned to aid the skilled man in carrying out the reactions described. The skilled man will appreciate however that a variety of different conditions, reagents, solvents, reactions etc could be used to effect the chemistry described and the conditions quoted are not intended to be limiting on the reactions described.

An alternative strategy involves the reaction of an alkoxy amide XCON(Oalkyl) with thiazole in base which affords 2-oxothiazoles directly. This reaction is summarised in scheme 2.

Scheme 2. (a) thiazole, base.

There are still further ways of developing a 2-oxo thiazole ring carrying a substituent. The ring itself can be generated from a thioamide as described in scheme 3.

Scheme 3. (a) TBDMSCN, KCN; (b) H2O2, BU4NHSO4; (c) Lawesson’s reagent; (d) BrCH2COCOOEt; (e) Dess Martin periodinane.

The formed compound can react with thiazole as described above.

Variations of the substituents on the heterocyclic rings and manipulation of the side chain binding the carbonyl can be achieved using all manner of synthetic techniques which the skilled man will know. Guidance is offered in the examples as to how to make a wide variety of compounds and the principles described can be extended to the compounds encompassed by the claims. WO2011/039365 also offers synthetic pathways to follow.

Reduction of the 2-oxothiazole to 2-hydroxylthiazole can be achieved using any suitable reducing agent.

Chronic Inflammatory Disorders

The compounds of the invention may be used in the prevention or treatment of chronic inflammatory disorders, in particular those associated with phospholipase inhibition.

Preferably, any compound of the invention will achieve at least 75%, such as at least 90% inhibition against group IVa PLA2.

Preferably, compounds of the invention inhibit group IVa cPLAi at a low μΜ range such as 5 μΜ or less, preferably 4 μΜ or less.

It is further preferred that the compounds of formula (I) of the invention show greater inhibition of group IVa CPLA2 than iPLA2 or SPLA2 according to published assays for these enzymes (see, for example, Yang, H et al. (1999) Anal. Biochem. 269: 278). Ideally, the compounds of the invention show limited or no inhibition of iPLA2 or SPLA2 and they are therefore highly specific for the group IVa CPLA2 enzyme.

Specific diseases of interest are glomerulonephritis, inflammatory dermatoses such as psoriasis and rheumatoid arthritis.

Further conditions of interest include other inflammatory dermatoses such as atopic dermatitis, allergic contact dermatitis, seborrheic dermatitis, pityriasis rosea, lichen planus and drug eruptions.

Furthermore the compounds of the invention may have use in the treatment of other types of arthritis and dermatoses, inflammatory CNS diseases, multiple sclerosis, chronic obstructive pulmonary disease, chronic lung inflammatory conditions, inflammatory bowel disease such as ulcerative colitis and crohns disease, and cardiovascular disease. Furthermore, the compounds of the invention may have use in the treatment of juvenile arthritis, Crohn’s colitis, psoriatic arthritis and ankylosing spondylitis.

Thus viewed from a further aspect the invention provides for the management (typically an alleviation of symptoms), prevention or treatment of any of the conditions listed above using the compounds of the invention.

In one embodiment, the prevention, treatment, or alleviation of symptoms of a chronic inflammatory condition such as those mentioned above can be achieved by administering at least one compound according to the invention (e.g., one, two or three of such compounds) to a subject as the sole active agent. Alternatively, the chronic inflammatory condition can be prevented, treated or symptoms alleviated along with at least one suitable anti-inflammatory drug (e.g., one, two or three of such drugs). Non-limiting examples of such drugs include certain steroids (e.g., corticosteroids), non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, ibuprofen and naproxen, and analgesics such as paracetamol, acetaminophen and the like; as well as ImSAIDs.

It will be appreciated that when the indication to be treated is rheumatoid arthritis or a related disorder, the subject may be receiving or will receive a disease modifying antirheumatic drug (known as DMARD) such as methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, and the like. In one embodiment, the DMARD can be administered along with at least one compound of the invention such as one, two or three of such compounds. In another embodiment, the subject can receive in addition to the DMARD a suitable biologic such as those mentioned below along with at least one compound of the invention such as one, two or three of such compounds. When a subject starts using a particular biologic agent, they will often also remain on their current dose of nonsteroidal anti-inflammatory (NS AID) and/or corticosteroid (i.e., prednisone) medicines.

It will be appreciated that therapeutic methods according to the invention are flexible and can be practiced in several ways to acheived a desired outcome. Thus in one embodiment, the method includes administering a compound having Formula I to a subject (e g., using an oral, i.v, i.p or other route) followed by administration of an anti-inflammatory drug as described herein. Use of a suitable biologic (e g. an antibody therapeutic as provided herein) may also be indicated. Alternatively, the method can be practiced by administering the anti-inflammatory drug first followed by administration of the compound of the invention. Choice of a particular methodology and administration route will be guided by understood parameters such as the chronic inflammatory disorder to be treated, age and sex of the subject, etc.

Hvperproliferative Disorders

In another aspect, the invention provides compounds of the invention for use in the management, treatment or prevention of any condition or clinical situation where it is desirable (or where it may be of benefit) to prevent or inhibit the growth of cells. Examples include tumors, cancers, neoplastic tissues, and other premaligant and noneoplastic hyperproliferative disorders, all of which together are referred to herein as hyperproliferative or hyperplastic disorders.

The term "inhibit" is used broadly to include any reduction or decrease in cell growth as well as the prevention or abolition of cell growth. "Inhibition" thus includes the reduction or prevention of cell growth. This may be determined by any appropriate or convenient means, such as determining or assessing cell number, size (e.g. size of tissue in which the cells are contained), cell viability and/or cell death etc., as may be determined by techniques well known in the art. "Growth" of cells as referred to herein is also used broadly to include any aspect of cell growth, including in particular the proliferation of cells.

The compounds of the invention may thus be used in the treatment of any condition (used broadly herein to include any disorder or any clinical situation) which is responsive to reduction of cell growth (particularly cell proliferation). The compounds accordingly find utility in any therapy (or treatment) which targets cell growth (or proliferation). In other words, the compounds may be used in any therapeutic application in which it desirable or advantageous to inhibit cell proliferation. A treatment may include any clinical step or intervention which contributes to, or is a part of, a treatment programme or regimen. A prophylactic treatment may include delaying, limiting, reducing or preventing the condition or the onset of the condition, or one or more symptoms thereof, for example relative to the condition or symptom prior to the prophylactic treatment. Prophylaxis thus explicitly includes both absolute prevention of occurrence or development of the condition, or symptom thereof, and any delay in the onset or development of the condition or symptom, or reduction or limitation on the development or progression of the condition or symptom. Treatment according to the invention thus includes killing, inhibiting or slowing the growth of cells, or the increase in size of a body or population of cells (e.g. in a tissue, tumour or growth), reducing cell number or preventing spread of cells (e.g. to another anatomic site), reducing the size of a cell growth etc. The term "treatment" does not imply cure or complete abolition or elimination of cell growth, or a growth of cells.

Since the therapeutic applications and utilities of the present invention may generally involve inhibiting cell proliferation, nearly any proliferating cell may be targeted in the therapies and utilities disclosed and encompassed herein. Such proliferating cells may include healthy or diseased cells and cells of any tissue in which proliferation occurs. For example, such cells may include in particular neoplastic cells, including both malignant and non-malignant neoplastic cells and cells of the immune system (immune cells), cells of the haematopoietic system generally, or skin cells.

The compounds of the invention can be employed to treat one or a combination of hyperproliferative disorders as the sole active agent or in combination with one or more other agents. In one embodiment, disorders or conditions involving abnormal or unwanted cell growth may be treated with known agents including known cytotoxic and/or cytostatic agents including chemotherapeutic agents. Accordingly, as alternatively stated above, the compounds of the invention may be used in any method of treatment which involves (or includes) the use of such cytotoxic and/or cytostatic agents. This may include the treatment of any condition responsive to a cytotoxic and/or cytostatic agent or any condition which may be treated with or which requires the use of such agent(s).

The treatment of hyperproliferative disorders represents an aspect of particular interest. The term "hyperproliferative disorder" is used broadly herein to include any disorder or condition which involves increased, undesired or unwanted proliferation of cells. Thus included are not only conditions in which proliferation of cells is increased, for example relative to normal or healthy cells, or cells in the absence of the condition in question (e g. compared or relative to a healthy or control subject, or compared or relative to cells taken from healthy or unaffected tissue in the same subject), but also conditions in which cell proliferation is not increased (or not greatly or significantly increased) over normal, but in which the proliferation which occurs is unwanted or undesired, whether generally or in a particular context. This may include for example an unwanted or undesired proliferation of cells which may occur in a "normal" response. A hyperproliferative disorder of particular interest involves the proliferation of cells which have the capacity for autonomous growth i .e. cells which exist and reproduce independently of normal regulatory mechanisms. A hyperproliferative disorder may therefore be a neoplastic disorder, and as noted above, this may be a pre-malignant, malignant, non-malignant or non-neoplastic disorder. Examples of pre-malignant or non-neoplastic or non-malignant hyperproliferative disorders include myelodysplastic disorders, cervical carcinoma-in-situ, familial intestinal polyposes (e.g. Gardner syndrome), oral leukoplasias, histiocytoses, keloids, hemangiomas, hyperproliferative arterial stenosis, inflammatory arthritis, hyperkeratoses, and papulosquamous eruptions, including arthritis. Also included are viral-induced hyperproliferative diseases such as warts and EBV-induced disease (e.g. infectious mononucleosis), scar formation and the like.

The hyperproliferative disorder may thus be any hyperproliferative disorder, for example selected from neoplastic disorders such as cancer (benign or metastatic). Cancer represents a hyperproliferative disorder of particular interest, and all types of cancers, including e.g. solid tumours and haematological cancers are included. Representative types of cancer include cervical cancer, uterine cancer, ovarian cancer, pancreatic cancer, kidney cancer, gallbladder cancer, liver cancer, head and neck cancer, squamous cell carcinoma, gastrointestinal cancer, breast cancer, prostate cancer, testicular cancer, lung cancer, non-small cell lung cancer, non-Hodgkin's lymphoma, multiple myeloma, leukemia (such as acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, and chronic myelogenous leukemia), brain cancer (e.g. astrocytoma, glioblastoma, medulloblastoma), neuroblastoma, sarcomas, colon cancer, rectum cancer, stomach cancer, anal cancer, bladder cancer, pancreatic cancer, endometrial cancer, plasmacytoma, lymphomas, retinoblastoma, Wilm’s tumor, Ewing sarcoma, melanoma and other skin cancers.

Mention may be made also of sinus tumours, urethral and genito-urinary cancers, oesophageal cancer, myeloma, endocrine cancers, osteosarcoma, angiosarcoma, and fibrosarcoma, and any tumour of the peripheral or central nervous systems, malignant or benign, including gliomas and neuroblastomas.

In embodiments in which the hyperproliferative disorder is a cancer, the invention also features methods of treating a subject (eg. a human that has or is suspected of having cancer) in which the method includes treating the subject with at least one compound of the invention, preferably one, two or three of such compounds alone or along with an effective amount of one or more agents having cytotoxic or cytostatic activity such as a chemotherapeutic agent (e g., one, two or three of such agents). Illustrative chemotherapeutic agents are “small molecules” selected from the group consisting of abiraterone acetate, altretamine, anhydrovinblastine, auristatin, bexarotene, bicalutamide, BMS184476, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulfonamide, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-proly- 1-Lproline-t-butylamide, cachectin, cemadotin, chlorambucil, cyclophosphamide, 3',4'-didehydro-4'-deoxy-8'-norvin- caleukoblastine, docetaxol, doxetaxel, cyclophosphamide, carboplatin, carmustine (BCNU),cisplatin, cryptophycin, cyclophosphamide, cytarabine, dacarbazine (DTIC), dactinomycin, daunorubicin, decitabine dolastatin, doxorubicin (adriamycin), etoposide, 5-fluorouracil, finasteride, flutamide, hydroxyurea and hydroxyureataxanes, ifosfamide, liarozole, lonidamine, lomustine (CCNU), MDV3100, mechlorethamine (nitrogen mustard), melphalan, mivobulin isethionate, rhizoxin, sertenef, streptozocin, mitomycin, methotrexate, 5-fluorouracil, nilutamide, onapristone, paclitaxel, prednimustine, procarbazine, RPRl09881, stramustine phosphate, tamoxifen, tasonermin, taxol, tretinoin, vinblastine, vincristine, vindesine sulfate, and vinflunine.

Other suitable chemotherapeutic agents for use with the invention include biologies such as immune molecules that exhibit a cytotoxic or cytostatic activity against a targeted cell or tissue. More specific examples include antibodies and antigen-binding fragments thereof, namely monoclonal, polyclonal, chimeric and humanized antibodies. Non-limiting examples include the following therapeutic antibodies that have been approved for human use for several medical indications:

Abciximab (ReoPro), Adalimumab (Humira), Alemtuzumab (Campath),

Basiliximab (Simulect), Belimumab (Benlysta), Bevacizumab (Avastin), Brentuximab vedotin (Adcetris), Canakinumab (Haris) Cetuximab (Erbitux), Certolizumab pegol (Cimzia), Daclizumab (Zenapax), Denosumab (Prolia, Xgeva), Eculizumab (Soliris), Efalizumab (Raptiva), Gemtuzumab (Mylotarg), Golimumab (Simponi), Ibritumomab tiuxetan (Zevalin), Infliximab (Remicade), Ipilimumab ( MDX-101 ) (Yervoy), Muromonab-CD3, (Orthoclone OKT3), Natalizumab (Tysabri), Ofatumumab (Arzerra), Omalizumab (Xolair), Palivizumab (Synagis), Panitumumab (Vectibix), Ranibizumab (Lucent! s), Rituximab (Rituxan, Mabthera)Tocilizumab ( or Atlizumab ) (Actemra and RoActemra), Tositumomab (Bexxar) and Trastuzumab (Herceptin).

Also included within the scope of suitable biologies for use with the invention are certain antibody-small molecule conjugates such as TDMl (conjugate of trastuzumab and doxorubicin).

In embodiments in which the hyperproliferative disorder is cancer and particularly a cancer of the breast, the chemotherapeutic drug may be selected from the following: Abitrexate (Methotrexate), Abraxane (Paclitaxel Albumin-stabilized Nanoparticle Formulation)Ado-Trastuzumab Emtansine, Adriamycin PFS (Doxorubicin Hydrochloride), Adriamycin RDF (Doxorubicin Hydrochloride), Adrucil (Fluorouracil), Afmitor (Everolimus), Anastrozole, Arimidex (Anastrozole), Aromasin (Exemestane), Capecitabine, Clafen (Cyclophosphamide), Cyclophosphamide, Cytoxan (Cyclophosphamide), Docetaxel, Doxorubicin Hydrochloride, Efudex (Fluorouracil), Ellence (Epirubicin Hydrochloride), Epirubicin Hydrochloride, Everolimus, Exemestane, Fareston (Toremifene),Faslodex (Fulvestrant), Femara (Letrozole), Fluoroplex (Fluorouracil), Fluorouracil, Folex (Methotrexate), Folex PFS (Methotrexate), Fulvestrant, Gemcitabine Hydrochloride, Gemzar (Gemcitabine Hydrochloride), Herceptin (Trastuzumab), Ixabepilone, Ixempra (Ixabepilone), Lapatinib Ditosylate, Letrozole, Methotrexate, Methotrexate EPF (Methotrexate), Mexate (Methotrexate), Mexate-AQ (Methotrexate), Neosar (Cyclophosphamide), Nolvadex (Tamoxifen Citrate), Novaldex(Tamoxifen Citrate), Paclitaxel, Paclitaxel Albumin-stabilized Nanoparticle Formulation, Peijeta (Pertuzumab), Pertuzumab, Tamoxifen Citrate,

Taxol (Paclitaxel), Taxotere (Docetaxel), Trastuzumab,Toremifene, Tykerb (Lapatinib Ditosylate), and Xeloda (Capecitabine)

In another aspect, the invention features methods of treating a subject (e.g. a human) having or suspected of having a hyperproliferative disorder such as cancer, involving administering to the subject an effective amount of a compound according to Formula I or II either as a sole agent or along with an effective amount of one or more chemotherapeutic agents described above (e.g., one, two or three of such agents). An illustrative treatment regimen involves treating, preventing or minimizing tumor progression or metastasis in a subject having a neoplasia, where the neoplastic cell is a cancer cell or is present in a tumor.

In another aspect, the invention features a method of treating, preventing or minimizing tumor progression or metastasis in a subject where the tumor is breast cancer, melanoma,, glioblastomas, colon cancer, non-small cell lung cancer, or lymphomas, involving administering to the subject an effective amount of at least one compound of the invention (e g., one, two or three of such compounds) alone or along with one or more other chemotherapeutic agents as described herein (e g, one or two of such agents).

In a particularly preferred embodiment, the invention relates to a method for preventing or treating breast cancer in a patient, the method comprising the steps of administering to the patient an effective amount of at least one chemotherapeutic agent; and administering an effective amount of at least one compound of the invention.

It is further preferred if a chemotherapeutic agent is administered to the patient before the administration of the compound of the invention, such as one or more of paclitaxel, doxorubicin, cyclophosphamide and cisplatin.

The method may also comprise the administration of one or more of trastuzumab (Herceptin), trastuzumab-doxorubicin conjugate (TDMl) and pertuzumab (Peijeta).

It will be appreciated that therapeutic methods according to the invention are flexible and can be practiced in several ways to acheived a desired outcome for the subject. Thus in one embodiment, the method includes administering a compound having Formula I or II to a subject (e.g., using an oral, i.v, i.p or other route) followed by administration of at least one chemotherapeutic agent as described herein (e g., one, two or three of such agents). Alternatively, the method can be practiced by administering the chemotherapeutic agent first followed by administration of the compound of the invention. Choice of a particular methodology and administration route will be guided by understood parameters such as the hyperproliferative disorder to be treated, age and sex of the subject, etc.

The method of the invention may also comprise the treatment or prevention of chronic inflammatory disorders associated a diabetic condition in a patient, particularly diabetes meilitus, such as diabetic nephropathy and diabetic retinopathy.

Subjects to be treated by the methods of the present invention include both human subjects (patients) and animal subjects for veterinary purposes. Animal subjects are generally mammalian subjects such as horses, dogs, cats, cows, rabbits, sheep and the like.

Screen

Suitable compounds for use with the present methods for treating, preventing or alleviating symptoms a hyperproliferative disorder can be selected by one or a combination of different strategies which are intended to detect and preferably quantify changes in cell proliferation when contacted by one or more invention compounds. Non-limiting examples of such screens are provided below: a. NCI60 Screen: In one approach, a compound of the invention is tested for efficacy in the NCI60 human humor cell line anticancer drug screen reported by Shoemaker, R. H (2006) Nat. Reviews Cancer 6, 813. Briefly, the NCI60 screen is a two-stage process, beginning with the evaluation of all compounds against 60 cell lines at a single dose of 10 μΜ. Compounds giving a growth inhibition of 50 % (GI50) is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, which is the compound concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the incubation. Preferred compounds of formula (I) or (II) of the invention have a GI50 of about 1-5μΜ in the NCI60 screen, more preferably about 0.01-0.1 μΜ or less with respect to at least one of the cell lines in the NCI60 screen.

See also Alley, M.C., et al. Cancer Research 48: 589-601, 1988; Grever, M R., et al. The National Cancer Institute: Cancer Drug Discovery and Development Program. Seminars in Oncology, Vol. 19, No. 6, pp 622-638, 1992; and Boyd, M.R., and Pauli, K.D. Some Practical Considerations and Applications of the National Cancer Institute In Vitro Anticancer Drug Discovery Screen. Drug Development Research 34: 91-109, 1995. b. Screen based on Clin Cancer Res. 2008 Dec 15;14(24):8070-9.

Patel MI, Singh J, Niknami M, Kurek C, Yao M, Lu S, Maclean F, King NJ, Gelb MH, Scott KF, Russell PJ, Boulas J, Dong Q.

In another approach the expression of cPLA2-alpha can be determined in prostate cancer cells by reverse transcription-PCR, Western blot, and immunocytochemistry. Growth inhibition, apoptosis, and cPLA2-alpha activity can be determined after inhibition with cPLA2-alpha small interfering RNA or inhibitor (Wyeth-1). Cytosolic PLA2-alpha inhibitor or vehicle can also be administered to prostate cancer xenograft mouse models. Finally, the expression of phosphorylated cPLA2-alpha can be determined by immunohistochemistry in human normal, androgen-sensitive and androgen-insensitive prostate cancer specimens.

Formulation

Irrespective of their intended use, the compounds of the invention are preferably formulated as pharmaceutically acceptable compositions. The phrase "pharmaceutically acceptable", as used in connection with compositions of the invention, refers to molecular entities and other ingredients of such compositions that are physiologically tolerable and do not typically produce untoward reactions when administered to a mammal (e.g. human). Preferably, as used herein, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in mammals, and more particularly in humans.

The term "carrier" applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active compound is administered. Such pharmaceutical carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, 18th Edition, incorporated by reference. Particularly preferred for the present invention are carriers suitable for immediate-release, i .e., release of most or all of the active ingredient over a short period of time, such as 60 minutes or less, and make rapid absorption of the drug possible.

Any compound of the invention can be administered in salt, solvate, prodrug or ester form, especially salt form. Typically, a pharmaceutical acceptable salt may be readily prepared by using a desired acid. The salt may precipitate from solution and be collected by filtration or may be recovered by evaporation of the solvent. For example, an aqueous solution of an acid such as hydrochloric acid may be added to an aqueous suspension of a compound of the invention and the resulting mixture evaporated to dryness (lyophilised) to obtain the acid addition salt as a solid. Alternatively, a compound of the invention may be dissolved in a suitable solvent, for example an alcohol such as isopropanol, and the acid may be added in the same solvent or another suitable solvent. The resulting acid addition salt may then be precipitated directly, or by addition of a less polar solvent such as diisopropyl ether or hexane, and isolated by filtration.

Suitable addition salts are formed from inorganic or organic acids which form non-toxic salts and examples are hydrochloride, hydrobromide, hydroiodide, sulphate, bi sulphate, nitrate, phosphate, hydrogen phosphate, acetate, trifluoroacetate, maleate, malate, fumarate, lactate, tartrate, citrate, formate, gluconate, succinate, pyruvate, oxalate, oxaloacetate, trifluoroacetate, saccharate, benzoate, alkyl or aryl sulphonates (eg methanesulphonate, ethanesulphonate, benzenesulphonate or p-toluenesulphonate) and isethionate. Representative examples include trifluoroacetate and formate salts, for example the bis or tris trifluoroacetate salts and the mono or diformate salts, in particular the tris or bis trifluoroacetate salt and the monoformate salt.

Those skilled in the art of organic chemistry will appreciate that many organic compounds can form complexes with solvents in which they are reacted or from which they are precipitated or crystallized. These complexes are known as "solvates". For example, a complex with water is known as a "hydrate". Solvates of the compounds of the invention are within the scope of the invention. The salts of the compound of the invention may form solvates (e.g. hydrates) and the invention also includes all such solvates.

The term "prodrug" as used herein means a compound which is converted within the body, e.g. by hydrolysis in the blood, into its active form that has medical effects.

The compounds of the invention are proposed for use in the treatment or prevention, inter alia, chronic inflammatory disorders and cancer. The compounds of the invention are also proposed for use in the treatment of, inter alia, cancer. By treating or treatment is meant at least one of (i) . inhibiting the disease i.e. arresting, reducing or delaying the development of the disease or a relapse thereof or at least one clinical or subclinical symptom thereof, or (ii) . relieving or attenuating one or more of the clinical or subclinical symptoms of the disease.

By prevention is meant (i). preventing or delaying the appearance of clinical symptoms of the disease developing in a mammal.

The benefit to a subject to be treated is either statistically significant or at least perceptible to the patient or to the physician. In general a skilled man can appreciate when "treatment" occurs.

The word "treatment" is also used herein to cover prophylactic treatment, i.e. treating subjects who are at risk of developing a disease in question.

The compounds can be used on any animal subject, in particular a mammal and more particularly to a human or an animal serving as a model for a disease (e.g. mouse, monkey, etc.).

An "effective amount" means the amount of a compound that, when administered to an animal for treating a state, disorder or condition, is sufficient to effect such treatment. The "effective amount" will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated and will be ultimately at the discretion of the attendant doctor.

While it is possible that, for use in the methods of the invention, a compound may be administered as the bulk substance, it is preferable to present the active ingredient in a pharmaceutical formulation, for example, wherein the agent is in admixture with a pharmaceutically acceptable carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

The term "carrier" refers to a diluent, excipient, and/or vehicle with which an active compound is administered. The pharmaceutical compositions of the invention may contain combinations of more than one carrier. Such pharmaceutical carriers can be sterile liquids, such as water, saline solutions, aqueous dextrose solutions, aqueous glycerol solutions, and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water or aqueous solution saline solutions and aqueous dextrose and glycerol solutions are preferably employed as carriers, particularly for injectable solutions. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin, 18th Edition. The choice of pharmaceutical carrier can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as, in addition to, the carrier any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), and/or solubilizing agent(s).

It will be appreciated that pharmaceutical compositions for use in accordance with the present invention may be in the form of oral, parenteral, transdermal, inhalation, sublingual, topical, implant, nasal, or enterally administered (or other mucosally administered) suspensions, capsules or tablets, which may be formulated in conventional manner using one or more pharmaceutically acceptable carriers or excipients.

There may be different composition/formulation requirements depending on the different delivery systems. Likewise, if the composition comprises more than one active component, then those components may be administered by the same or different routes.

The pharmaceutical formulations of the present invention can be liquids that are suitable for oral, mucosal and/or parenteral administration, for example, drops, syrups, solutions, injectable solutions that are ready for use or are prepared by the dilution of a freeze-dried product but are preferably solid or semisolid as tablets, capsules, granules, powders, pellets, pessaries, suppositories, creams, salves, gels, ointments; or solutions, suspensions, emulsions, or other forms suitable for administration by the transdermal route or by inhalation.

The compounds of the invention can be administered for immediate-, delayed-, modified-, sustained-, pulsed-or controlled-release applications.

In one aspect, oral compositions are slow, delayed or positioned release (e.g., enteric especially colonic release) tablets or capsules. This release profile can be achieved without limitation by use of a coating resistant to conditions within the stomach but releasing the contents in the colon or other portion of the GI tract wherein a lesion or inflammation site has been identified or a delayed release can be achieved by a coating that is simply slow to disintegrate or the two (delayed and positioned release) profiles can be combined in a single formulation by choice of one or more appropriate coatings and other excipients. Such formulations constitute a further feature of the present invention.

Pharmaceutical compositions can be prepared by mixing a therapeutically effective amount of the active substance with a pharmaceutically acceptable carrier that can have different forms, depending on the way of administration. Typically composition components include one or more of binders, fillers, lubricants, odorants, dyes, sweeteners, surfactants, preservatives, stabilizers and antioxidants.

The pharmaceutical compositions of the invention may contain from 0.01 to 99% weight - per volume of the active material. The therapeutic doses will generally be between about 10 and 2000 mg/day and preferably between about 30 and 1500 mg/day. Other ranges may be used, including, for example, 50-500 mg/day, 50-300 mg/day, 100-200 mg/day.

Administration may be once a day, twice a day, or more often, and may be decreased during a maintenance phase of the disease or disorder, e.g. once every second or third day instead of every day or twice a day. The dose and the administration frequency will depend on the clinical signs, which confirm maintenance of the remission phase, with the reduction or absence of at least one or more preferably more than one clinical signs of the acute phase known to the person skilled in the art.

It is within the scope of the invention for a compound as described herein to be administered in combination with another pharmaceutical, e.g. another drug with known efficacy against the disease in question. The compounds of the invention may therefore be used in combination therapy.

Alternatively, the compounds of formula (I) can be used as intermediates in the formation of other active compounds.

The invention will now be further described with reference to the following non limiting examples.

Example 1

N-Methoxy-2-(2-methoxyethoxy)-N-methylacetamide

To a solution of 2-(2-methoxyethoxy) acetic acid (2.68 g, 0.02 mol) in dry DCM (30 ml) was added thionyl chloride (3 ml, 0.041 mol). The reaction mixture was heated at reflux for 3 hours, concentrated to dryness and the crude acid chloride dissolved in DCM (30 ml) and cooled to 0 °C in an ice-bath. Triethylamine (6 ml, 0.044 mol) was added followed by A,(9-dimethylamine hydrochloride (2.11 g, 0.022 mol). When TLC showed complete formation of product the reaction mixture was concentrated directly and subjected to flash chromatography (EtOAc - EtOAc: MeOH gradient) to afford 1.89 g (55%) of the title compound.

2-(2-Methoxy ethoxy)-1 -(thiazol-2-yl)ethan-1 -one

To a solution of thiazole (170 mg, 2.0 mmol) in dry ether (5 ml) at -78 °C, was added BuLi (0.84 ml, 2.5 M, 2.1 mmol). The reaction mixture was stirred at -78 °C for 30 min., followed by addition of N-methoxy-2-(2-methoxyethoxy)-N-methylacetamide (361 mg, 2.1 mmol). The reaction mixture was allowed to reach room temperature and stirred for two hours. Aqueous HCl (25 ml, IM) was added and the aqueous phase extracted with EtOAc (x3). The combined organic extract was washed with water and brine, dried (Na2S04), filtered and concentrated. Flash chromatography (Heptane : EtOAc gradient) afforded 120 mg (30%) of the title compound as a yellow oil. NMR (400 MHz, CDC13) δ 7.95 (d, J= 3.0, IH), 7.67 (d, J= 3.0, IH), 5.01 (s, 2H), 3.84 - 3.70 (m, 2H), 3.69 - 3.51 (m, 2H), 3.34 (s, 3H) MS (electrospray): 224 [M+Na]"^

Example 2

2.5.8.1 l-Tetraoxatridecan-13-oic acid

To a solution of triethyleneglycol monomethyl ether (4.92 g, 30 mml) in dry THF (40 ml), was added sodium hydride (60%, 1.45 g, 36 mmol) at 0 °C. The solution was stirred for one hour at room temperature followed by slow addition of ethyl bromo acetate (6.01 g, 36 mmol). After stirring at 50 °C overnight, the reaction mixture was concentrated in vacuo and the residue hydrolyzed with 1 M LiOH (20 ml) and MeOH (20 ml) for 6 hours at room temperature. The solution was acidified with 1 M HCl to pH 1, and the solvents removed under reduced pressure. The residue was purified by flash chromatography (DCM : MeOH 90 : 10) to afford the 6.34 g (95%) of title compound as a colorless oil.

N-Methoxy-N-m ethyl -2,5,8,11 -tetraoxatri decan-13 -amide

To a solution of 2,5,8,1 l-tetraoxatridecan-13-oic acid (2.21 g, 10 mmol) in dry DCM (20 ml) was added DMF (100 μ1) followed by oxalyl chloride (1 ml, 11 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The residue was dissolved in DCM, cooled to 0 °C and N,0-dimethylhydroxylamine hydrochloride (1.07 g, 11 mmol) added followed by K2CO3 (3.04 g, 22 mmol). The reaction mixture was stirred for 3 hours, concentrated and purified directly by flash chromatography (EtOAc - EtOAc : MeOH gradient) to afford 1.57 g (59%) of the title compound.

13 -(Thiazol-2-yl)-2,5,8,11 -tetraoxatri decan-13 -one

To a solution of thiazole (170 mg, 2.0 mmol) in dry ether (10 ml) at -78 °C, was added BuLi (0.84 ml, 2.5 M, 2.1 mmol). The reaction mixture was stirred at -78 °C for 30 min., followed by addition of N-Methoxy-N-methyl-2,5,8,1 l-tetraoxatridecan-13-amide (557 mg, 2.1 mmol). The reaction mixture was allowed to reach room temperature and stirred for two hours. Aqueous HCl (25 ml, IM) was added and the aqueous phase extracted with EtOAc (x3). The combined organic extract was washed with water and brine, dried (Na2S04), filtered and concentrated. Flash chromatography (Heptane : EtOAc gradient) afforded 241 mg (42%) of the title compound as a orange oil. NMR (400 MHz, CDC13) δ 7.97 (d, 3.0, IH), 7.68 (d, 3.0, IH), 5.04 (s, 2H), 3.80 (dd, 5.8, 3.4, 2H), 3.72 (dd, 5.8, 3.4, 2H), 3.69 -3.64 (m, 2H), 3.64 - 3.59 (m, 2H), 3.51 (dd, 5.7, 3.6, 2H), 3.36 - 3.32 (m, 3H) MS (electrospray): 312 [M+Na]^

Example 3 The compound

is disclosed in WO2014/118195 as an intermediate (see compound 46).

Test Data

Materials and methods for performing the assays described in the example have been disclosed in WO2014/118195 (PCT/EP2014/051655) as well as referenced provided therein. In brief, % Inhibition for GIVA cPLA2 was measured at 0.091 mole fraction of each inhibitor. IC50 inhibitors for vesicle assay were tested at 0-3 μΜ concentration. Stability assay performed ex vivo using human plasma; % compound recovery following 4h and (24h) incubation. Slope of trendline for compound recovery in human plasma over 24h; a more negative slope indicates a faster compound removal in human plasma.

Claims (15)

1. Claims

   1. A compound of formula (I)

   wherein Rg is H, Ci-ealkyl, -(CH2)pCOOH, -(CH2)pCOOCi-6alkyl, -(CH2)pCONH2, -(CH2)pCONHCi-6alkyl, or -(CH2)pCON(Ci-6alkyl)2, Rio is H or Ci.6 alkyl; R2 is 0-(CH2)a-[0-(CH2)b]e-[0-(CH2)c]e-0-(CH2)dCH3; p is 0 to 3; a is 1 to 3, such as 2; b is 1 to 3, such as 2; c is 1 to 3, such as 2; d is 0 to 2, such as 0; each e is 0 or 1; or a salt, ester, solvate, N-oxide, or prodrug thereof
2. 2. A compound as claimed in claim 1 in which Re is H, -(CH2)pCOOH, -(CH2)pCONH2 or -(CH2)pCOOCi.ealkyl, preferably -COOCi-ealkyl or H.
3. 3. A compound as claimed in claim 1 or 2 in which Rio is preferably H.
4. 4. A compound as claimed in claim 1 to 3 wherein R2 is 0-(CH2)a-0-(CH2)b-0-(CH2)c-0-Me or -(CH2)a-0-Me, preferrably -OCH2CH2OCH3 or OCH2CH2-OCH2CH2-OCH2CH2-OCH3. AVX14
5. 5. A compound as claimed in claim 1 to 4 of formula (III)

   wherein Re is H, -(CH2)pCOOH, -(CH2)pCONH2 or -(CH2)pCOOCi.6alkyl; p is 0 or 1, especially 0; R2 is 0-(CH2)a-0-(CH2)b-0-(CH2)c-0-(CH2)dMe or -(CH2)a-0-(CH2)dMe; a is 1 to 3, such as 2; b is 1 to 3, such as 2; c is 1 to 3, such as 2; and d is 0 to 2, such as 0; or a salt, ester, solvate, N-oxide, or prodrug thereof
6. 6. A compound of formula (II)

   wherein R7 is H, Ci-ealkyl, -(CH2)pCOOH, -(CH2)pCOOCi.6alkyl, -(CH2)pCONH2, -(CH2)pCONHCi-6alkyl, or -(CH2)pCON(Ci-6alkyl)2, Rs is H or C1.6 alkyl· R9 is H, a Ci.ioalkyl group, -SCi.ioalkyl group or -OCi-ioalkyl group; and p is 0 to 3; AVX14 or a salt, ester, solvate, N-oxide, or prodrug thereof for use in the treatment or prevention of a chronic inflammatory condition or hyperproliferative disorder.
7. 7. A compound for use as claimed in claim 6 wherein R? is preferably H, -(CH2)pCOOH, -(CH2)pCONH2 or -(CH2)pCOOCi.6alkyl, preferably - COOCi-ealkyl.
8. 8. A compound for use as claimed in claim 6 or 7 wherein Rs is H.
9. 9. A compound for use as claimed in claim 6 to 8 wherein R9 is a Ci.ioalkyl group, -SCi-ioalkyl group or -OCi-ioalkyl group, especially a C4.10 alkyl group such as a C6-10 alkyl group.
10. 10. A compound for use as claimed in claim 6 to 9 of formula (IV):

    RvisH, -(CH2)pCOOH, -(CH2)pCONH2 or -(CH2)pCOOCi.6alkyl; p is 0 or 1; R9 is Ci-ioalkyl group, -SCi-ioalkyl group or -OCi-ioalkyl group, especially a C4.10 alkyl group such as a C6.10 alkyl group, especially

    or a salt, ester, solvate, N-oxide, or prodrug thereof AVX14
11. 11. A compound as claimed in claim 1 to 5 of formula

    or a salt, ester, solvate, N-oxide, or prodrug thereof
12. 12. A compound as claimed in claim 1 to 5 for use in therapy.
13. 13. A compound as claimed in any preceding claim for use in the treatment or prevention of a chronic inflammatory condition or hyperproliferative disorder.
14. 14. A pharmaceutical composition comprising a compound as claimed in claim 1 to 11.
15. 15. A method of treating or preventing a chronic inflammatory condition or hyperproliferative disorder in a patient comprising administering to a patient in need thereof an effective amount of a compound as claimed in claims 1 to 11.